Commerce Bank Buys 3,589 Shares of Horizon Therapeutics Public Limited (NASDAQ:HZNP)

Commerce Bank lifted its stake in shares of Horizon Therapeutics Public Limited (NASDAQ:HZNP) by 126.0% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 6,438 shares of the biopharmaceutical company’s stock after acquiring an additional 3,589 shares during the period. Commerce Bank’s holdings in Horizon Therapeutics Public were worth $705,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Mackenzie Financial Corp boosted its stake in shares of Horizon Therapeutics Public by 364.5% during the 3rd quarter. Mackenzie Financial Corp now owns 52,243 shares of the biopharmaceutical company’s stock worth $5,723,000 after acquiring an additional 40,996 shares in the last quarter. Vontobel Holding Ltd. boosted its stake in shares of Horizon Therapeutics Public by 22.7% during the 3rd quarter. Vontobel Holding Ltd. now owns 13,392 shares of the biopharmaceutical company’s stock worth $1,467,000 after acquiring an additional 2,478 shares in the last quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp bought a new stake in shares of Horizon Therapeutics Public during the 2nd quarter worth about $15,911,000. State Street Corp boosted its stake in shares of Horizon Therapeutics Public by 24.8% during the 2nd quarter. State Street Corp now owns 5,450,915 shares of the biopharmaceutical company’s stock worth $510,424,000 after acquiring an additional 1,083,282 shares in the last quarter. Finally, Private Capital Group LLC boosted its stake in shares of Horizon Therapeutics Public by 15.6% during the 3rd quarter. Private Capital Group LLC now owns 2,615 shares of the biopharmaceutical company’s stock worth $286,000 after acquiring an additional 353 shares in the last quarter. Institutional investors own 88.00% of the company’s stock.

In other news, CEO Timothy P. Walbert sold 25,000 shares of the stock in a transaction that occurred on Friday, January 14th. The stock was sold at an average price of $90.02, for a total value of $2,250,500.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Timothy P. Walbert sold 50,000 shares of the stock in a transaction that occurred on Tuesday, November 30th. The stock was sold at an average price of $102.40, for a total value of $5,120,000.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 148,255 shares of company stock valued at $15,633,956. 3.20% of the stock is currently owned by insiders.

Several analysts have recently issued reports on HZNP shares. Jefferies Financial Group began coverage on Horizon Therapeutics Public in a research note on Wednesday, October 13th. They set a “buy” rating and a $132.00 price target for the company. The Goldman Sachs Group upgraded Horizon Therapeutics Public from a “neutral” rating to a “buy” rating and set a $168.00 target price for the company in a research note on Thursday, November 18th. Zacks Investment Research downgraded Horizon Therapeutics Public from a “buy” rating to a “hold” rating and set a $124.00 target price for the company. in a research note on Friday, October 29th. Finally, Wells Fargo & Company began coverage on Horizon Therapeutics Public in a research note on Wednesday, December 8th. They set an “overweight” rating and a $137.00 target price for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat, Horizon Therapeutics Public currently has an average rating of “Buy” and an average price target of $126.75.

Horizon Therapeutics Public stock opened at $91.10 on Friday. The business has a 50 day moving average price of $103.99 and a two-hundred day moving average price of $105.63. The company has a quick ratio of 2.55, a current ratio of 2.83 and a debt-to-equity ratio of 0.57. The stock has a market cap of $20.66 billion, a price-to-earnings ratio of 39.27, a price-to-earnings-growth ratio of 0.78 and a beta of 1.03. Horizon Therapeutics Public Limited has a 12 month low of $70.15 and a 12 month high of $120.54.

Horizon Therapeutics Public (NASDAQ:HZNP) last posted its quarterly earnings results on Wednesday, November 3rd. The biopharmaceutical company reported $1.75 EPS for the quarter, beating the consensus estimate of $1.54 by $0.21. The firm had revenue of $1.04 billion during the quarter, compared to analysts’ expectations of $979.49 million. Horizon Therapeutics Public had a return on equity of 26.85% and a net margin of 18.66%. The company’s revenue for the quarter was up 62.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.74 EPS. On average, analysts expect that Horizon Therapeutics Public Limited will post 4.29 earnings per share for the current fiscal year.

About Horizon Therapeutics Public

Horizon Therapeutics Plc is a biopharmaceutical company, which is engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Rheumatology, and Inflammation segments. The Orphan and Rheumatology segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS.

Recommended Story: Why do companies issue convertible shares?

Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Therapeutics Public Limited (NASDAQ:HZNP).

Institutional Ownership by Quarter for Horizon Therapeutics Public (NASDAQ:HZNP)

Receive News & Ratings for Horizon Therapeutics Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics Public and related companies with MarketBeat.com's FREE daily email newsletter.